Cadence Pharmaceuticals Inc. Jan. 18 announced that it has launched Ofirmev (acetaminophen) injection, the first and only intravenous formulation of acetaminophen to be approved in the United States.
The Food and Drug Administration approved Ofirmev in November 2010 for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever (8 PLIR 1412, 11/5/10).
Ofirmev now is available to hospitals across the United States, the San Diego-based company said.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.